DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyone in anyway? What's going on? #ACR21 @RheumNow https://t.co/IMr5ee2Iea

Billing and coding expert, Jean Acevedo shares the three URLs that you need to best understand the updated 2021 EM coding! #ACR21 @RheumNow #RheumNow https://t.co/3HbDuZP8gC

Pulmonary Arterial Hypertension in #AOSD Rare but severe complication - life threatening French study of 13 pts - network dataset. ALL FEMALES! Age 32, mean f/u 34 mths, 5 pts (38.5%) DIED @RheumNow #ACRBest abst#1100 https://t.co/5LIzHagesP

Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21 https://t.co/7DPGsVB6bG https://t.co/F57k44AWZ4

• https://bit.ly/3Hafuvg

Knowledge Bowl at #ACR21 ⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis. ➡️Amyopathic (MDA5) dermatomyositis @RheumNow

Knowledge Bowl at #ACR21 ⭐️In a suspected PAN case, you order a peripheral smear to look for this potential etiology, ➡️Hairy cells @RheumNow

JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to second JAKi? Both seem equally effective in terms of drug retention. Didn't matter if switch for efficacy or adverse event. Abstr#1442 #ACR21 @RheumNow https://t.co/QEBB3flArC

#ACR21 Abs#1442: JAKpot - Cycle JAK or switch to bDMARD after JAK failure? ▶️No difference between cycle vs bDMARD group ▶️Non-signif trends: cycled JAK better for inefficacy to 1st JAK, bDMARD better for adverse effects @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/upfI6tDH1p

• https://bit.ly/3qk9MB2

First JAKi failure: What's next? Wanna find out? It's here https://t.co/o5CE1MBzUu Abstr#1442 #ACR21 @RheumNow https://t.co/f0sdPn5mcZ

• First JAKi Failure: What next? Dr. Aurelie Najm | RheumNow

Trauma associates with subsequent increased flares of SLE. Abstr#1446 #ACR21 @RheumNow https://t.co/QeNXOjHAjn

Tell me there's no collegiality on the #ACR21 virtual platform! kudos to @ACRheum for making this thing run so smoothly, year-on-year (and I'm telling you, the value's in the chat and the questions) @RheumNow @Janetbirdope https://t.co/XJZArHIdnc

Can you win the JAK pot twice? Equal effectiveness of JAK to JAK in #RheumatoidArthritis vs JAK to bDMARD. If d/c due to AE w JAK seemed to recur w 2nd JAK. Not RCT ?Channeling bias. But JAKi were worse off at baseline but did= switch v swap #ACR21 #ACRBest abst#1442 @RheumNow https://t.co/SRXMHdUBJF

Dr Jafarzadeh @Tuhina_Neogi on association NSAID use with TKR. At same level of pain, NSAID users appear to have more TKR. Is this same phenomenon we see with IA steroids (and tanezumab?)⬇️pain⬆️use⬆️damage? Abstr#1447 #ACR21 @RheumNow https://t.co/oY2ckmui0D